NCT00448721View on ClinicalTrials.gov

A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2011

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Perifosine

Perifosine will be administered orally at 100mg PO daily with food.

Trial Locations (4)

19104

Investigative Site, Philadelphia

37232

Investigative Site, Nashville

91010

Investigative Site, Duarte

02115

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

AEterna Zentaris
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

AEterna Zentaris

INDUSTRY

NCT00448721 - A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer | Biotech Hunter | Biotech Hunter